Literature DB >> 17890096

Tumor immunolocalization using 124 I-iodine-labeled JAA-F11 antibody to Thomsen-Friedenreich alpha-linked antigen.

Richa Chaturvedi1, Jamie Heimburg, Jun Yan, Stephen Koury, Munawwar Sajjad, Hani H Abdel-Nabi, Kate Rittenhouse-Olson.   

Abstract

Clinical immunolocalization has been attempted by others with an anti-Thomsen-Friedenreich antigen (TF-Ag) mAb that bound both alpha- and beta-linked TF-Ag. In this report, 124 I-labeled mAb JAA-F11 specific for alpha-linked TF-Ag showed higher tumor specificity in in vivo micro-positron emission tomography (micro-PET) of the mouse mammary adenocarcinoma line, 4T1, showing no preferential uptake by the kidney. Labeled product remained localized in the tumor for at least 20 days. Glycan array analysis showed structural specificity of the antibody.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17890096      PMCID： PMC3192430          DOI： 10.1016/j.apradiso.2007.07.029

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN： 0969-8043            Impact factor:   1.513


  20 in total

1.  Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments.

Authors:  P J Yazaki; A M Wu; S W Tsai; L E Williams; D N Ikler; J Y Wong; J E Shively; A A Raubitschek
Journal:  Bioconjug Chem       Date:  2001 Mar-Apr       Impact factor: 4.774

2.  The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography.

Authors:  David R Collingridge; Veronica A Carroll; Mathias Glaser; Eric O Aboagye; Safiye Osman; Oliver C Hutchinson; Henryk Barthel; Sajinder K Luthra; Frank Brady; Roy Bicknell; Pat Price; Adrian L Harris
Journal:  Cancer Res       Date:  2002-10-15       Impact factor: 12.701

3.  Pre-operative assessment of axillary lymph node status in patients with breast adenocarcinoma using intravenous 99mtechnetium mAb-170H.82 (Tru-Scint AD).

Authors:  S Dessureault; I Koven; R M Reilly; J Couture; B Schmocker; M Damani; J Kirsh; M Ichise; S Sidlofsky; A J McEwan; G Boniface; H Stern; S Gallinger
Journal:  Breast Cancer Res Treat       Date:  1997-08       Impact factor: 4.872

4.  In vivo localization of radioiodinated peanut lectin in a murine TA3/Ha mammary carcinoma model.

Authors:  A Shysh; S M Eu; A A Noujaim; M R Suresh; B M Longenecker
Journal:  Eur J Nucl Med       Date:  1985

5.  Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.

Authors:  Tomohide Tatsumi; Jian Huang; William E Gooding; Andrea Gambotto; Paul D Robbins; Nikola L Vujanovic; Sean M Alber; Simon C Watkins; Hideho Okada; Walter J Storkus
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

6.  Effect of salivary gland adenocarcinoma cell-derived alpha-N-acetylgalactosaminidase on the bioactivity of macrophage activating factor.

Authors:  Takashi Matsuura; Takashi Uematsu; Minoru Yamaoka; Kiyofumi Furusawa
Journal:  Int J Oncol       Date:  2004-03       Impact factor: 5.650

7.  Monoclonal antibodies and synthetic tumor-associated glycoconjugates in the study of the expression of Thomsen-Friedenreich-like and Tn-like antigens on human cancers.

Authors:  B M Longenecker; D J Willans; G D MacLean; S Selvaraj; M R Suresh; A A Noujaim
Journal:  J Natl Cancer Inst       Date:  1987-03       Impact factor: 13.506

8.  Radioiodinated peanut lectin: clinical use as a tumour-imaging agent and potential use in assessing renal-tubular function.

Authors:  E A Abdi; V J Kamitomo; T A McPherson; Z Catz; G Boniface; B M Longenecker; A A Noujaim
Journal:  Eur J Nucl Med       Date:  1986

9.  Comparative radiolabeling and distribution of a tumour-directed monoclonal antibody.

Authors:  C J Turner; T R Sykes; B M Longenecker; A A Noujaim
Journal:  Int J Rad Appl Instrum B       Date:  1988

10.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575
View more
  14 in total

Review 1.  Simple sugars to complex disease--mucin-type O-glycans in cancer.

Authors:  Matthew R Kudelka; Tongzhong Ju; Jamie Heimburg-Molinaro; Richard D Cummings
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

Review 2.  Cancer vaccines and carbohydrate epitopes.

Authors:  Jamie Heimburg-Molinaro; Michelle Lum; Geraldine Vijay; Miten Jain; Adel Almogren; Kate Rittenhouse-Olson
Journal:  Vaccine       Date:  2011-10-01       Impact factor: 3.641

3.  Therapeutic efficacy of the humanized JAA-F11 anti-Thomsen-Friedenreich antibody constructs H2aL2a and H3L3 in human breast and lung cancer xenograft models.

Authors:  Diala Ghazal; Fatma Zalzala; John C Fisk; Swetha Tati; Loukia G Karacosta; Susan Morey; James R Olson; Sally Quataert; Grace K Dy; Kate Rittenhouse-Olson
Journal:  Oncotarget       Date:  2022-10-19

4.  Sugar-binding proteins from fish: selection of high affinity "lambodies" that recognize biomedically relevant glycans.

Authors:  Xia Hong; Mark Z Ma; Jeffrey C Gildersleeve; Sudipa Chowdhury; Joseph J Barchi; Roy A Mariuzza; Michael B Murphy; Li Mao; Zeev Pancer
Journal:  ACS Chem Biol       Date:  2012-10-08       Impact factor: 5.100

5.  Preclinical evaluation of the novel monoclonal antibody H6-11 for prostate cancer imaging.

Authors:  Hongjun Jin; Mai Xu; Prashanth K Padakanti; Yongjian Liu; Suzanne Lapi; Zhude Tu
Journal:  Mol Pharm       Date:  2013-09-03       Impact factor: 4.939

6.  Development, characterization, and immunotherapeutic use of peptide mimics of the Thomsen-Friedenreich carbohydrate antigen.

Authors:  Jamie Heimburg-Molinaro; Adel Almogren; Susan Morey; Olga V Glinskii; Rene Roy; Gregory E Wilding; Richard P Cheng; Vladislav V Glinsky; Kate Rittenhouse-Olson
Journal:  Neoplasia       Date:  2009-08       Impact factor: 5.715

7.  Monte Carlo Calculation of Radioimmunotherapy with (90)Y-, (177)Lu-, (131)I-, (124)I-, and (188)Re-Nanoobjects: Choice of the Best Radionuclide for Solid Tumour Treatment by Using TCP and NTCP Concepts.

Authors:  S Lucas; O Feron; B Gallez; B Masereel; C Michiels; T Vander Borght
Journal:  Comput Math Methods Med       Date:  2015-06-02       Impact factor: 2.238

8.  Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and InVitro Efficacy Analysis.

Authors:  Swetha Tati; John C Fisk; Julia Abdullah; Loukia Karacosta; Taylor Chrisikos; Padraic Philbin; Susan Morey; Diala Ghazal; Fatma Zazala; Joseph Jessee; Sally Quataert; Stephen Koury; David Moreno; Jing Ying Eng; Vladislav V Glinsky; Olga V Glinskii; Muctarr Sesay; Anthony W Gebhard; Karamveer Birthare; James R Olson; Kate Rittenhouse-Olson
Journal:  Neoplasia       Date:  2017-08-19       Impact factor: 5.715

9.  Preclinical Analysis of JAA-F11, a Specific Anti-Thomsen-Friedenreich Antibody via Immunohistochemistry and In Vivo Imaging.

Authors:  Loukia G Karacosta; John C Fisk; Joseph Jessee; Swetha Tati; Bradley Turner; Diala Ghazal; Rachel Ludwig; Holly Johnson; Julia Adams; Munawwar Sajjad; Steven Koury; Rene Roy; James R Olson; Kate Rittenhouse-Olson
Journal:  Transl Oncol       Date:  2018-02-22       Impact factor: 4.243

10.  Computational screening of the human TF-glycome provides a structural definition for the specificity of anti-tumor antibody JAA-F11.

Authors:  Matthew B Tessier; Oliver C Grant; Jamie Heimburg-Molinaro; David Smith; Snehal Jadey; Andrew M Gulick; John Glushka; Susan L Deutscher; Kate Rittenhouse-Olson; Robert J Woods
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.